Melinta Therapeutics Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela® (delafloxacin), Vabomere® (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. This portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.
Company profile
Ticker
MLNTQ
Exchange
Website
CEO
Jennifer A. Sanfilippo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cempra Holdings, LLC, Cempra, Inc.
SEC CIK
Corporate docs
IRS number
262644445
MLNTQ stock data
Latest filings (excl ownership)
SC TO-T/A
Third party tender offer statement (amended)
24 Jun 20
SC TO-T
Third party tender offer statement
12 Jun 20
S-3DPOS
Registration of securities, dividend or interest reinvestment plans, immediately effective (post-effective amendment)
20 Apr 20
S-3DPOS
Registration of securities, dividend or interest reinvestment plans, immediately effective (post-effective amendment)
20 Apr 20
S-3DPOS
Registration of securities, dividend or interest reinvestment plans, immediately effective (post-effective amendment)
20 Apr 20
S-3DPOS
Registration of securities, dividend or interest reinvestment plans, immediately effective (post-effective amendment)
20 Apr 20
S-3DPOS
Registration of securities, dividend or interest reinvestment plans, immediately effective (post-effective amendment)
20 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Apr 20
Latest ownership filings
3
Ryan Lococo
25 Oct 19
3
Susan Blum
25 Oct 19
3
Jennifer A Sanfilippo
13 Sep 19
SC 13D/A
Melinta Therapeutics, Inc. /New/
12 Aug 19
SC 13G/A
Melinta Therapeutics, Inc. /New/
10 Jul 19
4
JOHN JOHNSON
2 Jul 19
SC 13D/A
Melinta Therapeutics, Inc. /New/
2 Jul 19
4
JOHN JOHNSON
26 Jun 19
4
Kevin Ferro
12 Jun 19
4
BRUCE DOWNEY
12 Jun 19
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|